Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Drugs In Clinical Trials

Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Drug: Sabcomeline (SB-202026)
Mode of action: M1 agonist
Phase: Inactive
Company:
Note: Previously used in Alzheimer's disease

Useful Links:

Loudon RP, Perussia B, Benovic JL. Differentially regulated expression of the G-protein-coupled receptor kinases, betaARK and GRK6, during myelomonocytic cell development in vitro. Blood . 1996 Dec 15 ; 88(12):4547-57. Abstract

Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol . 2006 May 16 ; 47(10):1919-26. Abstract

Hatcher JP, Loudon JM, Hagan JJ, Clark MS. Sabcomeline (SB- 202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze. Psychopharmacology (Berl). 1998 Aug;138(3-4):275-82. Abstract

Harries MH, Samson NA, Cilia J, Hunter AJ. Related The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset. Br J Pharmacol. 1998 May;124(2):409-15. Abstract

Bromidge SM, Brown F, Cassidy F, Clark MS, Dabbs S, Hadley MS, Hawkins J, Loudon JM, Naylor CB, Orlek BS, Riley GJ. Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo [2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere. J Med Chem. 1997 Dec 19;40(26):4265-80. Abstract


November 1, 2014
SRF News
SRF Comments
Text Size
Reset Text Size
Share/Bookmark

See our upcoming webinar, Cognition and Treatment Resistance in Schizophrenia, to be held Monday, November 10, 12:00 to 1:30 p.m. EST.

See our last webinar, Research Domain Criteria (RDoC) Applied to Verbal Hallucinations, held May 28, 2014.

Check out our Schizophrenia Bulletin Forum Discussion: Prefrontal Inefficiency Is Associated With Polygenic Risk for Schizophrenia.
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright